Unmatched Global Insights and Local Market Granularity

Rare Disease Analytics & Insights service supports biopharmaceutical commercial teams challenged with the launch and growth of rare disease therapies.

Our comprehensive offering delivers in depth insights on patients, providers, and competitive dynamics across 26 therapeutic areas in up to 50 countries.

Get in touch

The Competitive Advantage

The unmatched stakeholder network across 50 countries delivers granular insights into patient, provider and channel segments, enabling development of targeted offensive and defensive market strategies for competitive advantage in healthcare markets.

Global Network

Our unparalleled global rare disease network includes thousands of stakeholders involved in the complex decision-making process of treating and caring for patients impacted by rare diseases.

Therapeutic area stakeholders

Key Opinion Leaders (KOLs)
Patients and Caregivers
Practice Managers, Operations, and Admin
Our panelists share details related to treatment decisions and market conditions

Audit Platform

The Audit Platform provides robust EMR-derived and survey-based data for up-to-date patient, provider, and competitive treatment analytics and tracking.
‍

Various settings of care

HCP offices, clinics, infusion centers, HOPD
Hospitals (academic/regional), IDNs, COEs
Specialty pharmacies, distributors
Monthly and quarterly patient and performance audits

Expert Insights

The program leaders are experts in each of their therapeutic areas and serve as advisory partners to biopharma commercial and medical teams.

‍

Actionable insights and strategy

Synthesis of qualitative and quantitative data derived from our network and audits
Supports development of abstracts, appropriate use, and HEOR publication strategies
Geographically diverse offices for local support

Our Rare Disease Analytics & Insights services transform data with unmatched coverage, accuracy, and granularity into actionable intelligence for rare disease markets.

Our data has unmatched coverage, accuracy and granularity in rare disease markets

Coverage Map of Hereditary Angioedema (HAE)

Strategic Analysis and Insights Delivered

Market Opportunity

Identify high‐value patient segments and specialized centers for improved diagnosis and referrals
Develop competitive positioning strategies for both global and local HAE markets

Patient Population

Quantify prevalence, diagnosed prevalence, and subtype segmentation
Calculate treated patients by therapy type (unique vs. concomitant) to reveal usage patterns

KOL/Prescriber Identification & Targeting

Map prescriber expertise and patient volume to prioritize engagement
Understand prescribing protocols and rationale to tailor messaging and support

Patient Dx / Patient Journey

Identify who diagnoses (e.g., specialists vs. primary care), where, and key referral triggers
Clarify testing trends and severity staging to pinpoint critical decision points
Uncover barriers and drivers shaping HAE diagnosis and referral pathways

Sites / Settings of Care

Define how and where each HAE treatment is administered, including specialized equipment/staffing
Analyze key drivers and constraints that move patients toward specialty centers
Conduct channel assessments (Centers of Excellence, academic hospitals, specialty pharmacies, etc.)

Treatment Segmentation

Evaluate regimens (On‐Demand vs. Prophylaxis), routes (SC, Oral, IV), and therapy types (mAbs, C1‐INH, etc.)
Track brand‐switching behaviors and underlying reasons (efficacy, safety, convenience)
Highlight best practices in product selection, switching dynamics, and ongoing patient management

HAE Audit and Insights Platform – Example Outputs

Insightful performance tracking enables our clients to respond to dynamic market conditions in a timely manner.

These graphics are only a select group from our client-facing insights library. This information has been simulated as a representation of the insights we deliver for HAE.

Get in touch

Coverage Map

Strategic Analysis and Insights Delivered

Total Market Tracking

Indications: Hem A, Hem B, vWD, Inhibitors, AHA, Glanzmann’s, FVII Deficiency
Severity: Severe, Moderate, Mild
Therapies: FVIII and FIX concentrates (EHLs and SHLs), FVIII-Mimetics, Non-Factor Rebalancing Agents, Bypassing Agents (BPAs), Gene Therapy

KOL/Prescriber Identification & Targeting

Provider expertise
Patient volume
Prescribing protocols and preferences
Practice-specific insights and decision-making rationale

Market Driver Analysis

Brand switch analysis by age, severity, payer, and switch reason
Identify trends in treatment infusion frequency to inform positioning of new products
Define key drivers, restraints and trends in treatment of each therapy type
Channel assessment (HTC, specialty pharmacy, etc.)